stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) EPS (diluted)
Teva Pharmaceutical Industries Ltd.'s EPS (diluted) for fiscal 2025 was $1.21, compared with −$1.45 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.43. Over the past ten years it has ranged from −$16.26 (fiscal 2017) to $1.82 (fiscal 2015); the current reading is higher than 91% of that period. Teva Pharmaceutical Industries Ltd. ranks 21st of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.21 | — |
| FY2024 | −$1.45 | — |
| FY2023 | −$0.50 | — |
| FY2022 | −$2.12 | — |
| FY2021 | $0.38 | — |
| FY2020 | −$3.64 | — |
| FY2019 | −$0.91 | — |
| FY2018 | −$2.35 | — |
| FY2017 | −$16.26 | — |
| FY2016 | $0.07 | (96.15%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.20 | — |
| Jun 2026 | −$0.49 | — |
| Mar 2026 | $0.31 | (24.39%) |
| Dec 2025 | $0.41 | 10.81% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $26.50 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| TAK Takeda Pharmaceutical Co. compare | $0.66 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| TEVA Teva Pharmaceutical Industries Ltd. | $0.43 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TEVA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement